MIRA INFORM REPORT
|
Report Date : |
03.05.2013 |
IDENTIFICATION DETAILS
|
Name : |
ABBOTT HEALTHCARE PRIVATE LIMITED (w.e.f.08.05.2002) |
|
|
|
|
Formerly Known
As : |
KNOLL INTERNATIONAL PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
Unit No.4, Corporate Park, Sion, |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.12.2011 |
|
|
|
|
Date of
Incorporation : |
01.01.1997 |
|
|
|
|
Com. Reg. No.: |
11-104834 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 21.560
Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24200MH1997PTC104834 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMK06799C |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACK3935D |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical Products. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
B (36) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 410000000 |
|
|
|
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a subsidiary of “Abbott Asia Holding Limited, UK”. It is an
established company having a moderate track record. The company has incurred huge loss from its operations during 2011. However, trade relations are fair. Business is active. Payments are
reported as slow but correct. The company can be considered for business dealings with some
caution. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
LOCATIONS
|
Registered Office : |
Unit No.4, Corporate Park, Sion, Trombay Road, Chembur, Mumbai –
400071, Maharashtra, India |
|
Tel. No.: |
91-22-67978888 |
|
Fax No.: |
91-22-67978733/ 67978727 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Branch Office 1 : |
12, Corporate Park, Sion-Trombay Road, Mumbai - 400 071,
Maharashtra, India |
|
Tel No. : |
91-22-67978831 |
|
Fax. No. : |
91-22-67978921 |
|
|
|
|
Branch Office 2 : |
Diagnostics Office No. 201, Everest Grande, Opposite Ahura Centre, Mahakali Road, Andheri (East), Mumbai – 400069, Maharashtra, India |
|
Tel No. : |
91-22-66754132 / 33 |
|
Fax. No. : |
91-22-66790468 |
|
|
|
|
Branch Office 3 : |
Nutritional
Products 11th Floor , Hall Mark Plaza, Near Gurunanak Hospital, Bandra (East), Mumbai – 400 051, Maharashtra, India |
|
Tel No. : |
91-22-67566000 |
|
Fax. No. : |
91-22-67576060 |
|
|
|
|
Branch Office 4 : |
Vascular Office Floor, The Surya, New Friends Colony, New Delhi - 110025 India |
|
Tel. No.: |
91-22-40530100 |
|
Fax No.: |
91-22-40530198/ 199 |
|
|
|
|
Branch Office 5 : |
Healthcare Solutions 1st floor, D Mart Building, Goregaon - Mulund Link Road, Mumbai – 400080, Maharashtra, India |
|
Tel No. : |
91-22-39536666 |
|
Fax. No. : |
91-22-39536845 |
|
|
|
|
Branch Office 6 : |
True Care 1st Floor, Su Motors Complex, Model Town, Bal Rajeshwar Marg, Mulund (West), Mumbai – 400080, Maharashtra, India |
|
Tel No. : |
91-22-30781000 |
|
Fax. No. : |
91-22-30781080 |
|
|
|
|
Branch Office 7 : |
Medical Optics The Masterpiece Lavel – 5, Golf Course Road, Sector - 54, Gurgaon - 122002, Haryana, India |
DIRECTORS
As on: 29.06.2012
|
Name : |
Mr. Thomas Craig Freyman |
|
Designation : |
Director |
|
Address : |
912, |
|
Date of Birth/Age : |
08.09.1954 |
|
Date of Appointment : |
02.05.2003 |
|
DIN No.: |
00654517 |
|
|
|
|
Name : |
Mr. Rajesh Upendra Pandya |
|
Designation : |
Director |
|
Address : |
B/23, 5th Floor, Sangam Apartment, 161 Versova Lane,
Andheri (west), Mumbai – 400053, Maharashtra, India |
|
Date of Birth/Age : |
13.12.1963 |
|
Date of Appointment : |
01.09.2005 |
|
DIN No.: |
00096606 |
|
|
|
|
Name : |
Mr. Sudarshan K Jain |
|
Designation : |
Director |
|
Address : |
Flat No. 101, 1st Floor, Jamunamahal Colony, Santacruz
(East), Mumbai – 400055, Maharashtra, India |
|
Date of Birth/Age : |
06.06.1955 |
|
Qualification : |
MBA |
|
Date of Appointment : |
25.07.2011 |
|
DIN No.: |
00927487 |
KEY EXECUTIVES
|
Name : |
Mr. Kiran M Ravi |
|
Designation : |
Secretary |
|
Address : |
2B,92, Kalpataru, |
|
Date of Birth/Age : |
18.08.1977 |
|
Date of Appointment : |
01.09.2009 |
|
PAN No.: |
AFLPM7387Q |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on: 29.06.2012
|
Names of Shareholders |
|
No. of Shares |
|
Abbott Asia Holding Limited, United Kingdom |
|
2380998 |
|
Abbott Capital India Limited, United Kingdom |
|
2 |
|
|
|
|
|
Total |
|
2381000 |
Allotees As on: 21.12.2012
|
Names of Allotees |
|
No. of Shares |
|
Abbott Asia Holding Limited,
United Kingdom |
|
266930 |
|
|
|
|
|
Total |
|
266930 |
Equity Share Break up (Percentage of Total Equity)
As on: 29.06.2012
|
Category |
|
Percentage |
|
|
|
|
|
Foreign holdings [Foreign institutional investors, Foreign Companies, Foreign Financial Institutions, Non-resident Indian or Overseas corporate bodies or others] |
|
100.00 |
|
|
|
|
|
Total
|
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Products. |
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
||||||||||||
|
|
|
||||||||||||
|
Bankers : |
Standard Chartered Bank, 90 M G Road, Fort, Mumbai - 400001,
Maharashtra, India |
||||||||||||
|
|
|
||||||||||||
|
Facilities : |
(Rs.
In Millions)
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Financial
Institution : |
BNP Paribas, French Bank Building, Fort, Mumbai – 400001, |
|
|
|
|
Auditors : |
|
|
Name : |
Deloitte Hanskins and sells Chartered Accountants |
|
Address : |
12, |
|
Tel. No.: |
91-22-66679000 |
|
Fax No.: |
91-22-66679100 |
|
PAN No.: |
AACFD4815A |
|
|
|
|
Holding Company : |
Abbott Asia Holdings Limited, UK |
|
|
|
|
Ultimate Holding
Company: |
Abbott Laboratories, USA |
|
|
|
|
Other related parties
with whom transactions have taken place during the period : |
|
CAPITAL STRUCTURE
After: 29.06.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
29700000 |
Equity Shares |
Rs.10/- each |
Rs.297.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2647930 |
Equity Shares |
Rs.10/- each |
Rs. 26.479
Millions |
|
|
|
|
|
As on: 31.12.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
29700000 |
Equity Shares |
Rs.10/- each |
Rs.297.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
2156000 |
Equity Shares |
Rs.10/- each |
Rs. 21.560
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.12.2011 |
31.12.2010 |
31.11.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
21.560 |
5.000 |
5.000 |
|
|
2] Share Application Money |
18352.100 |
107637.200 |
0.000 |
|
|
3] Reserves & Surplus |
107802.280 |
329.344 |
1260.179 |
|
|
4] (Accumulated Losses) |
(22523.094) |
0.000 |
0.000 |
|
|
NETWORTH |
103652.846 |
107971.544 |
1265.179 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1.746 |
0.000 |
0.000 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
1.746 |
0.000 |
0.000 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
394.493 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
103654.592 |
108366.037 |
1265.179 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
155294.430 |
173280.749 |
336.160 |
|
|
Capital work-in-progress |
1129.417 |
799.700 |
0.832 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
35.986 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
3552.286
|
2418.480 |
465.524
|
|
|
Sundry Debtors |
2384.010
|
2006.659 |
508.289
|
|
|
Cash & Bank Balances |
8968.044
|
5727.870 |
804.495
|
|
|
Other Current Assets |
80.654
|
21.202 |
1.539
|
|
|
Loans & Advances |
1481.383
|
1073.970 |
191.180
|
|
Total
Current Assets |
16466.377
|
11248.181 |
1971.027 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
1206.930
|
868.073 |
656.814 |
|
|
Other Current Liabilities |
66765.060
|
75045.049 |
388.392 |
|
|
Provisions |
1263.642
|
1049.471 |
33.620 |
|
Total
Current Liabilities |
69235.632
|
76962.593 |
1078.826 |
|
|
Net Current Assets |
(52769.255)
|
(65714.412) |
892.201 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
103654.592 |
108366.037 |
1265.179 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.12.2011 |
31.12.2010 |
31.11.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Sales |
27318.849 |
12134.402 |
4116.374 |
|
|
|
Other Income |
NA |
NA |
NA |
|
|
|
TOTAL |
NA |
NA |
NA |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Office Expenses |
|
|
|
|
|
|
Administrative Expenses |
|
|
|
|
|
|
Advertising Expenses |
|
|
|
|
|
|
TOTAL |
NA |
NA |
NA |
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
BEFORE TAX |
(23077.915) |
(310.258) |
221.708 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
(407.242) |
620.577 |
85.250 |
|
|
|
|
|
|
|
|
|
|
PROFIT / (LOSS)
AFTER TAX |
(22670.673) |
(930.835) |
136.458 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
147.579 |
1078.414 |
941.956 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
(22523.094) |
147.579 |
1078.414 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Reimbursement of Expenses |
NA |
NA |
2.553 |
|
|
TOTAL EARNINGS |
9323.010 |
NA |
2.553 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Finished Goods |
|
NA |
2077.237 |
|
|
|
Stores & Spares |
|
NA |
13.089 |
|
|
|
Capital Goods |
|
NA |
117.329 |
|
|
TOTAL IMPORTS |
47096.420 |
NA
|
2207.655 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
(9521.49) |
(1861.67) |
NA |
|
KEY RATIOS
|
PARTICULARS |
|
31.12.2011 |
31.12.2010 |
31.11.2009 |
|
Net Profit Margin (PBT/Sales) |
(%) |
(84.48) |
(2.56)
|
5.39 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
(13.43) |
(0.17)
|
9.48 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
(0.22) |
(0.00)
|
0.18 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt/Networth) |
|
0.00 |
0.00
|
0.00 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
0.23 |
0.15
|
1.82 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info
Agents |
Available in Report
(Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
No |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
No |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
Date of Birth of Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
No |
NOTE
Registered Office Address of the company has been shifted from Unit No.3
and 4 Corporate Parksion Trombay Road, Chembur, Mumbai – 400071, Maharashtra,
India to present w.e.f. 13.07.2009
AS PER WEBSITE DETAILS
Press Release
Abbott Completes Acquisition of Piramal's Healthcare Solutions Business, Becomes Leading Pharmaceutical Company in India
Abbott Park, Illinois (NYSE: ABT) — Abbott has completed its acquisition of Piramal's Healthcare Solutions business, propelling it to market leadership in the Indian pharmaceutical market and further accelerating the company's growth in emerging markets.
Throughout the past decade, Abbott has established a leading presence in emerging markets – today, more than 20 percent of the company's total sales are generated in these growing economies.
"The acquisition of Piramal's Healthcare Solutions business further strengthens Abbott's growing presence in emerging markets," said Miles D. White, chairman and chief executive officer, Abbott. "Piramal's portfolio of well-known, trusted products has served patients in India for decades. Combined with existing product offerings, Abbott is uniquely positioned to meet the needs of one of the world's fastest-growing pharmaceutical markets."
India's rapid pharmaceutical market growth is being driven largely by branded generics. The market will generate nearly $8 billion in pharmaceutical sales this year, a number that is expected to more than double by 2015. Abbott expects its pharmaceutical sales in India to exceed $2.5 billion by 2020.
Piramal's Healthcare Solutions business has a comprehensive portfolio of branded generics, including market-leading brands in multiple therapeutic areas, including antibiotics, respiratory, cardiovascular, pain and neuroscience.
The Healthcare Solutions business will operate as a separate business unit, reporting into Abbott's newly-created Established Products Division (EPD), which was formed to focus on branded generics, maximizing the opportunity in emerging markets. The business will continue to be led by its current India-based management team.
"Piramal's proven business model in India and experienced local leadership team, combined with the global resources of Abbott, will allow us to build upon Piramal's commitment to quality and service," said Michael J. Warmuth, senior vice president, Established Products, Pharmaceutical Products Group, Abbott.
Abbott now employs approximately 10,000 people across all of its businesses in India.
Abbott, through a wholly-owned subsidiary, purchased the assets of Piramal's Healthcare Solutions business for a $2.2 billion up-front payment with additional payments of $400 million annually for the next four years, beginning in 2011. This transaction will not impact Abbott's ongoing earnings per share guidance in 2010.
About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
FIXED ASSETS
- Leasehold Improvement
- Machinery and Equipments
- Vehicles
- Furniture, Fittings and Office Equipments
- Goodwill
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or anti-terrorism
sanction laws or whose assets were seized, blocked, frozen or ordered forfeited
for violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 56.50 |
|
|
1 |
Rs. 86.01 |
|
Euro |
1 |
Rs. 73.68 |
INFORMATION DETAILS
|
Report Prepared
by : |
DPH |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
4 |
|
OPERATING SCALE |
1~10 |
4 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
4 |
|
--PROFITABILIRY |
1~10 |
3 |
|
--LIQUIDITY |
1~10 |
4 |
|
--LEVERAGE |
1~10 |
4 |
|
--RESERVES |
1~10 |
4 |
|
--CREDIT LINES |
1~10 |
4 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
|
|
|
|
TOTAL |
|
36 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.